bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-3419

Order Name:
SigNatera initial test, Tissue (FFPE) + Blood **

 
Useful For:
Detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer.
 
Methodology:
Detect ctDNA by tracking 16, tumor-specific clonal variants based on WES + PCR + NGS
 
 
 
Test Code:
090-71-3419

Order Name:
SigNatera initial test, Tissue (FFPE) + Blood **

 
Collection Specimen Or Container:
FFPE Tissue 6-10 Slide/or tissue block + H&E slide
+ Blood (SigNatera Kit) - Two 10mL Streck tubes + 6mL EDTA tube

Document Required
- Filled Requisition Form & Sign Consent 
 
Specimen Testing Type:
FFPE Tissue 6-10 Slide/or tissue block + H&E slide
+ Whole blood 10mL Streck x 2 tubes + 6mL EDTA tube
 
Sub Mission Container:
SigNatera tissue collection Kit  +  SigNatera blood collection Kit
 
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood Ambient temperature 7 days *
* Sent to USA
 
 
 
Test Code:
090-71-3419

Order Name:
SigNatera initial test, Tissue (FFPE) + Blood **

 
Method detail:
Detect ctDNA by tracking 16, tumor-specific clonal variants based on WES + PCR + NGS
 
Schedule:
N/A **Sent out to Natera, Inc., USA
 
 
Turnaround Time:
Received specimen to reported within 5 weeks (Slide received to report)
 
Performing Location:
Natera, Inc.
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-3419

Order Name:
SigNatera initial test, Tissue (FFPE) + Blood **

 
 
Clinical Information:
“Signatera Test” means Natera’s individual-specific screening test for detecting and monitoring circulating tumor DNA in the plasma of patients previously diagnosed with cancer. Individual-specific mutation signatures are identified by upfront FFPE tissue and matched-normal whole exome sequencing.

Signatera Setup consists of whole exome sequencing of tissue and matched-normal in order to determine the individual-specific mutation signature, to be measured with the Initial Plasma Test and monitored with Subsequent Plasma Tests.
 
Clinical Reference:
www.natera.com/oncology/signatera-clinicians (Retrieved: 22 Jul 2020)